AstraZeneca: presents new clinical data at AAN

(CercleFinance.com) - Alexion and AstraZeneca will present new clinical and real-world data from its leading rare neurology portfolio at the American Academy of Neurology (AAN) annual meeting in Denver from 13-18 April 2024.


The company will present 14 abstracts, including five oral presentations, covering both generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

The presentations include new long-term results from the pivotal Phase III CHAMPION-MG and CHAMPION-NMOSD trials, as well as real-life data, adding to the strong evidence supporting the safety and efficacy of Ultomiris (ravulizumab) and Soliris (eculizumab) in gMG and NMOSD.

Christophe Hotermans, Senior Vice President and Head of Global Medical Affairs at Alexion, said that Ultomiris and Soliris bring innovation and hope to the gMG and NMOSD communities, offering treatment options with the potential to transform care for these debilitating diseases.

He added that the company's data at AAN will present results in clinical and real-world settings that clearly demonstrate the lasting benefit of Ultomiris and Soliris in these patient populations. We remain committed to advancing care and innovative solutions for people with these rare neurological diseases.


Copyright (c) 2024 CercleFinance.com. All rights reserved.